
|Articles|April 22, 2004
Aastrom Biosciences Inc. receives Phase I Small Business Innovation Research Grant (SBIR)
Aastrom Biosciences Inc. announced that it has received a Phase I Small Business Innovation Research Grant (SBIR) grant from the National Institutes of Health National Cancer Institute to develop an immunotherapeutic treatment of malignant melanoma using its AastromReplicell System cell production technology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Updates iPLEDGE REMS with New Modifications for Pregnancy Testing and Prescription Windows
2
Targeting MRGPRX2: Early Human Data for a Novel CSU Approach
3
Precision Medicine Arrives in Atopic Dermatitis: Guiding Systemic Treatment Decisions Through Gene Expression Profiling
4
Phase 3 Results Signal a New Era for Oral Targeted Therapy in Psoriasis
5










